Loading...
 
Back to the list
Mediterr J Rheumatol 2018;29(3):170-2
Article Links
Canakinumab for refractory RA: a case report
Nikolaos Marketos1,2,3, Ilias Bournazos2,3, Dimitrios Ioakimidis2,3
Authors Information

1. Department of Rheumatology, University Hospital of Linköping, Linköping, Sweden

2. Private Practice Rheumatologist, Athens, Greece

3. Rheumatology Outpatient Department, Henry Dunant Hospital Centre, Athens, Greece

Keywords: Rheumatoid arthritis, joint erosion, Canakinumab
References
  1. Aletaha D, Neogi T, Silman A J, Funovits J, Felson D T, Bingham C O, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81. [https://doi.org/10.1002/art.27584] [PMID: 20872595]
  2. Dayer J M. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford) 2003;42:ii3-i10. [https://doi.org/10.1093/rheumatology/keg326] [PMID: 12817089]
  3. Geyer M, Müller-Ladner U. Actual status of antiinterleukin-1 therapies in rheumatic diseases. Curr Opin Rheumatol 2010;22:246-51. [https://doi.org/10.1097/BOR.0b013e3283373fa0] [PMID: 20150813]
  4. Ait-Oudhia S, Lowe P J, Mager D E. Bridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL-1β Kinetics. CPT Pharmacometrics Syst Pharmacol 2012;1:e5. [https://doi.org/10.1038/psp.2012.6] [PMID: 23835885]
  5. Dubois E A, Rissmann R, Cohen A F. Rilonacept and canakinumab. British Journal of Clin Pharmacol 2011;71:639-41. [https://doi.org/10.1111/j.1365-2125.2011.03958.x] [PMID: 21375570]
  6. Alten R, Gomez-Reino J, Durez P, Beaulieu A, Sebba A, Krammer G, et al. Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study. BMC Musculoskelet Disord 2011;12:153. [https://doi.org/10.1186/1471-2474-12-153] [PMID: 21736751]
  7. Dhimolea E. Canakinumab. mAbs 2010;2:3-13. [PMID: 20065636]
  8. Ridker P M, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011;162:597-605. [https://doi.org/10.1016/j.ahj.2011.06.012] [PMID: 21982649]
  9. Cavalli G, Dinarello C A. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford) 2015;54:2134-44.  [https://doi.org/10.1093/rheumatology/kev269] [PMID: 26209330]
  10. Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, Cattalini M, et al. A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: A nationwide multi-center retrospective observational study. Front Pharmacol 2016;7. [https://doi.org/10.3389/fphar.2016.00380] [PMID: 27822185]